{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-011852","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.743403+00:00","generated_at":"2026-05-26T22:48:46.363494+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kala Bio CEO Mark Iwicki resigns; Todd Bazemore named interim CEO","bullets":["Mark Iwicki resigned as CEO effective Feb 11, 2025; remains Chair of Board.","Board appointed Todd Bazemore as interim CEO and principal executive officer, effective immediately.","Bazemore had been President since Dec 2021 and COO since Nov 2017.","Prior roles include EVP/COO at Santhera and EVP/Chief Commercial Officer at Dyax."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-011852","json":"https://secwatch.observer/filing/0001104659-25-011852.json","markdown":"https://secwatch.observer/filing/0001104659-25-011852.md","text":"https://secwatch.observer/filing/0001104659-25-011852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/0001104659-25-011852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/tm256232d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:48:46.363494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d014f028b","claim":"Mark Iwicki resigned as Chief Executive Officer at KALA BIO, Inc..","evidence_excerpt":"On February 11, 2025, Mark Iwicki notified KALA BIO, Inc. (the “Company”) of his decision to resign as the Chief Executive Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/0001104659-25-011852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a90250eeb4","claim":"Todd Bazemore was appointed as interim Chief Executive Officer and principal executive officer at KALA BIO, Inc..","evidence_excerpt":"On February 11, 2025, the Board appointed Todd Bazemore as the interim Chief Executive Officer and principal executive officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/0001104659-25-011852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer and principal executive officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}